PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novo Nordisk once-weekly insulin hits phase 3 goals

Novo Nordisk announced positive headline results from a pair of phase 3a trials with once-weekly insulin, icodec, in adults with type 2 diabetes.

The once-weekly basal insulin is designed to cut down on the number of injections endured by people with type 2 diabetes. It is being studied in six phase 3a global clinical trials, known as the ONWARDS program.

ONWARDS 3 is a double-blind 26-week efficacy and safety treat-to-target trial investigating icodec vs Novo’s insulin degludec, branded Tresiba. The trial found that from an overall baseline hemoglobin A1c of 8.5%— a measure of blood sugar — icodec achieved a superior reduction in estimated HbA1c of –1.57% compared with –1.36% for Tresiba.

ONWARDS 4 is a 26-week efficacy and safety treat-to-target trial investigating icodec vs insulin glargine U100, both in combination with mealtime insulin. The trial found that from a baseline HbA1c of 8.3%, icodec achieved a reduction in estimated HbA1c of –1.16% compared with –1.18% for insulin glargine.

Novo says it will share the results from the last remaining ONWARDS program — ONWARDS 5 — in the second half of this year.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026